Galapagos NV
http://www.glpg.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Galapagos NV
Finance Watch: Frontier Raises $80m For Differentiated KRAS G12C Program
Private Company Edition: With its lead program in the clinic, Frontier’s $80m series C round will fund trials for additional programs. Also, ORI raises $260m for second fund, Earlybird closed a €173m ($187.1m) fund, Areteia’s series A grew to $425m and Sudo’s series B increased to $147m.
In Vivo’s Deals Of The Year: Cast Your Vote!
It is time for In Vivo's 16th annual Deals of the Year contest. We've selected 12 nominees across three categories – Top M&A, Top Alliance and Top Financing – and you get to pick the winners.
Deal Watch: Coherus Terminates Immuno-Oncology Alliance With Junshi
Plus deals involving Menarini/VenatoRx, Orion/Glykos, Roche/MOMA, Janssen/Elektrofi, Galapagos/BridGene along with 13 other transactions.
VC Fundraising Fell In Q4 But There Are Glimmers Of Hope For 2024
Evaluate’s fourth quarter data show that biopharma venture capital fundraising fell from $4.28bn in in Q3, but there was a rise in smaller deals and financial market conditions are poised for a turnaround.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Technologies
- Large Molecule
- Other Names / Subsidiaries
-
- Abound Bio, Inc.
- CellPoint B.V.
- Discovery Partners International
- Inpharmatica Ltd.
- Sareum Holdings plc.
- ProSkelia
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice